查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1694059

PTPN2抑制劑:策略性市場洞察和開發平台的展望-2025年

PTPN2 Inhibitors: Strategic Market Insights & Pipeline Outlook - 2025
出版日期: | 出版商: Mellalta Meets LLP | 英文 100 Pages | 商品交期: 5-7個工作天內

價格
簡介目錄

多年來，PTPN2 一直被稱為 "無法用藥" 的標靶。 PTPN2 抑制劑目前正成為免疫療法中很有希望的候選藥物。許多公司正在積極致力於開發這些小分子化合物，這個領域的問題不再是 "是否" 的問題，而是這些化合物 "多快" 才能達到有意義的臨床驗證。

免疫檢查點抑制劑市場規模目前在 2023 年價值 484.2 億美元，預計到 2030 年將達到 1542.5 億美元，由於癌症發病率上升、醫療保健支出增加以及檢查點抑製劑的使用範圍擴大，複合年增長率為 17.9%。

檢查點抑制劑（PD-1、PD-L1、CTLA-4）徹底改變了癌症治療，但該行業現在面臨一個新的現實：並非所有腫瘤都有反應。 PTPN2 抑制劑不是阻斷細胞表面的受體，而是在細胞內部發揮作用，促進 T 細胞活化。這種細胞內免疫調節可能為標準免疫療法失敗的患者提供新的反應。

ABBV-CLS-484（AbbVie/Calico）目前正在進行晚期實體瘤的臨床試驗。 AbbVie 和 Calico Life Sciences 擴大了合作，額外投資 10 億美元，專注於老化和與年齡相關的疾病，包括癌症。勃林格殷格翰以 13 億美元收購 Nerio Therapeutics，加倍押注 PTPN1 和 PTPN2。

Eilean Therapeutics 收購 Ness Therapeutics，以開發具有更高安全性的一流 PTPN2 抑制劑。 Eilean Therapeutics 擴大與 Expert Systems 的合作，整合人工智慧驅動的藥物發現，以加速 PTPN2 抑制劑的開發。

本報告提供全球PTPN2抑制劑市場相關調查，提供市場現狀，以及收購，授權及聯盟契約，競爭情形，市場機會等資訊。

目錄

第1章 報告書概要

第2章 概要

  • PTPN2抑制劑的介紹與作用
  • 關於 PTPN2 抑制劑的潛在擔憂
  • PTPN2 抑制劑：腫瘤學中極有前景的標靶
  • PTPN2抑制劑的臨床應用

第3章 PTPN2抑制劑開發平台分析

  • 概要
  • 適應症/階段劃分的資產
  • 依開發階段劃分的管道產品
  • PTPN2抑制劑競爭格局
  • 公司和階段劃分的管道產品
  • PTPN2抑制劑臨床及監管時間表

第4章 PTPN2抑制劑的收購，授權及聯盟契約

  • PTPN2抑制劑的收購，授權及交易價值
  • PTPN2抑制劑的收購，授權(各交易類型，各期總額)
  • 正在開發的有前途的技術

第5章 PTPN2抑制劑開發平台的形勢

  • 簡介概要
  • 後期階段的資產比較概要
  • PTPN2抑制劑開發平台藥物簡介
    • ABBV CLS 579(AbbVie/Calico Life Sciences)
    • ABBV CLS 484(AbbVie/Calico Life Sciences)
    • AB-1015(Arsenal bio)
    • HDM 2010(Hangzhou Zhongmei Huadong Pharmaceutical)
    • PTPN2抑制劑(Eilean Therapeutics)
    • PTPN1/N2抑制劑(Boehringer Ingelheim)
    • 其他

第6章 PTPN2抑制劑的未來展望

第7章 SWOT分析

第8章 附錄

簡介目錄

For years, PTPN2 has been labeled as an "undruggable" target-a challenge too complex, a surface too shallow. But the industry has learned that what was undruggable yesterday becomes tomorrow's breakthrough, and PTPN2 inhibitors are now emerging as a serious contender in immunotherapy. With many companies actively developing these small molecules, the field is no longer about "if" but "how fast" these assets can reach meaningful clinical validation.

The immune checkpoint inhibitors market is currently valued at $48.42 billion in 2023, projected to reach $154.25 billion by 2030, growing at a CAGR of 17.9% due to the rising cancer prevalence, increased healthcare expenditure, and expanding applications of checkpoint inhibitors.

The Science: What Makes PTPN2 Different?

Checkpoint inhibitors (PD-1, PD-L1, CTLA-4) revolutionized cancer care, but the industry is now facing a new reality-not all tumors respond. PTPN2 inhibitors offer an alternative, working inside the cell to enhance T-cell activation instead of blocking receptors on the surface. This intracellular immune modulation could unlock new responses in patients who fail standard immunotherapies.

The Market: A Race for Clinical Validation

Despite their potential, PTPN2 inhibitors are still in early-stage development-but the right players are making big bets:

  • ABBV-CLS-484 (AbbVie/Calico) is in trials for advanced solid tumors. AbbVie and Calico Life Sciences extended their partnership with an additional $1 billion investment, focusing on aging and age-related diseases, including oncology.
  • Boehringer Ingelheim made a $1.3 billion move by acquiring Nerio Therapeutics, doubling down on PTPN1 and PTPN2.
  • Eilean Therapeutics acquired Ness Therapeutics, aiming to develop best-in-class PTPN2 inhibitors with improved safety profiles. Eilean Therapeutics expanded its collaboration with Expert Systems, integrating AI-driven drug discovery to accelerate PTPN2 inhibitor development

Challenges & Development Hurdles

Despite promising therapeutic potential, PTPN2 inhibitors face key development challenges:

  • Unfavorable pharmacokinetics, due to the highly cationic active site and shallow protein surface.
  • Clinical uncertainties, with many candidates in early-stage trials requiring further validation.
  • Need for combination therapies, often tested alongside anti-PD-1 therapies to enhance efficacy.

Market & Pipeline Insights: 2025 Report Highlights

The PTPN2 Inhibitor - Pipeline Analytics 2025 Report by Mellalta Meets provides an in-depth analysis of the market opportunity and competitive landscape across multiple indications, including oncology, cardiovascular, and cognitive disorders.

Key coverage areas include:

  • Competitive Analysis - Breakdown of Companies and Products (Discovery to phase III)
  • Pipeline Drug Profiles - Stages of development, intervention types, clinical trials
  • Clinical Developments - Trials by region, efficacy outcomes, safety considerations
  • Business & Investment Trends - Licensing agreements, funding, and collaborations
  • Strategic Opportunities - Market drivers, challenges, and future outlook
  • Recent and upcoming events

Table of Content

1. REPORT OVERVIEW

2. OVERVIEW

  • 2.1. Introduction and Role of PTPN2 inhibitors
  • 2.2. Potential Concern with PTPN2 inhibitors
  • 2.3. PTPN2 inhibitors: A Highly-Potential Target in Oncology
  • 2.4. Clinical Applications of PTPN2 inhibitors

3. PTPN2 INHIBITOR PIPELINE ANALYSIS

  • 3.1. Overview
  • 3.2. Assets by Indication/Phase
  • 3.3. Pipeline Products by Stage of Development
  • 3.4. PTPN2 inhibitor Competitive Landscape
  • 3.5. Pipeline Products by Company and Phases
  • 3.6. PTPN2 inhibitor Clinical & Regulatory Timelines

4. PTPN2 INHIBITOR ACQUISITIONS, LICENSING AND COLLABORATION DEALS

  • 4.1. PTPN2 inhibitor Acquisitions, Licensing and Deal values
  • 4.2. PTPN2 inhibitor Acquisitions, Licensing by Transaction type and total amount size by Phases
  • 4.3. Promising Technologies Under development

5. PTPN2 inhibitor PIPELINE LANDSCAPE

  • 5.1. Profile at Glance
  • 5.2. Late-Stage Assets Comparisons At-a-glance
  • 5.3. PTPN2 inhibitor Pipeline Drug Profiles
    • 5.3.1. ABBV CLS 579 (AbbVie/Calico Life Sciences)
      • 5.3.1.1. Product Profile & Description
      • 5.3.1.2. Collaborations
      • 5.3.1.3. Other Developments
      • 5.3.1.4. Clinical Trials
    • 5.3.2. ABBV CLS 484 (AbbVie/Calico Life Sciences)
      • 5.3.2.1. Product Profile & Description
      • 5.3.2.2. Collaborations
      • 5.3.2.3. Other Developments
      • 5.3.2.4. Clinical Trials
    • 5.3.3. AB-1015 (Arsenal bio)
      • 5.3.3.1. Product Profile & Description
      • 5.3.3.2. Collaborations
      • 5.3.3.3. Other Developments
      • 5.3.3.4. Clinical Trials
    • 5.3.4. HDM 2010 (Hangzhou Zhongmei Huadong Pharmaceutical)
      • 5.3.4.1. Product Profile & Description
      • 5.3.4.2. Collaborations
      • 5.3.4.3. Other Developments
    • 5.3.5. PTPN2 inhibitors (Eilean Therapeutics)
      • 5.3.5.1. Product Profile & Description
      • 5.3.5.2. Collaborations
      • 5.3.5.3. Other Developments
    • 5.3.6. PTPN1/N2 inhibitors (Boehringer Ingelheim)
      • 5.3.6.1. Product Profile & Description
      • 5.3.6.2. Collaborations
      • 5.3.6.3. Other Developments
    • 5.3.7. Others...

6. PTPN2 INHIBITOR FUTURE PROSPECTS

7. SWOT ANALYSIS

8. APPENDIX